news roundup
World Courier, a global provider of specialty logistics and a part of AmerisourceBergen, will open a new investigational drug depot in Moscow, Russia, in August.
|
advertisment
Partnerships in Clinical Trials USA 2016, celebrating its 25th year. October 5-7 / Boston Convention Center. Push Novel Drugs to Market through Clinical Trials Innovation, Technology and Strategic Relationships. Spotlight session on Zika.
 Learn more and register here
|
As a PPD subsidiary, Evidera will deliver peri- and post-approval studies, health economics, outcomes research, epidemiology and market access consulting.
|
advertisment
 Click here to watch a short video about Covance's Xcellerate Informatics platform, an innovative 4-module solution to optimize the planning and execution of clinical trials.
|
OmniComm Systems announces the selection of its Trial One platform by a pharmaceutical company to automate its Phase I and BA/BE clinic.
|
advertisment
Simplifying the complexities of global rare disease drug development
Live Webinar: Thursday, September 15 at 11:00 EDT
 Register now
|
|
|
|
|
advertisment
Transforming Patient Recruitment through Patient and Site Engagement
Live Webinar: Tuesday, August 23, 2016 at 11 am – 12 noon EDT
 Register now
|
Subscribe
|
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
Articles
In this interview, Mony Weschler, Chief Technology and Innovation Strategist at Montefiore, elaborates on his experiences with successfully piloting and deploying mHealth technologies.
Modeling and simulation (M&S), also known as biosimulation or model-informed drug discovery and development, can deliver significant business, scientific and clinical value to firms that fully utilize it as an integral part of their drug development strategy.
|
|
Blog Posts
When cluster randomized trials (CRT) involve interventions at a cluster level, informed consent from participants may not always be possible to obtain.
|
|
Oncology
In oncology trials, censoring occurs when there is a difference between the investigator's determination of the time of disease progression versus the core laboratory's interpretation, resulting in a form of missing data.
A start-up biotech will use Medidata's Rave in two of its upcoming Phase I and Phase II trials of an experimental monoclonal cancer drug to be tested in solid tumor and blood cancers.
The objective of this new era of precision medicine coupled with advancing technologies is enabling new trial designs that match patients to the right genomic- or immune-targeted drugs.
The White House Precision Medicine Initiative's Cancer MoonShot program migrates from the realm of fantasy, to distinct possibility, and perhaps, to reality through a merger of information technology and genetic science.
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
